AI assistant
Sending…
Kairos Pharma, LTD. — Director's Dealing 2024
Nov 22, 2024
34903_dirs_2024-11-21_a81a3d6f-9a93-48b8-a525-11cf71dfaf25.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Kairos Pharma, LTD. (KAPA)
CIK: 0001962011
Period of Report: 2024-11-20
Reporting Person: Yu John S (Director, CEO and Chairman, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-11-20 | COMMON STOCK | P | 4000 | $1.44 | Acquired | 5341837 | Direct |
More from Kairos Pharma, LTD.
Proxy Solicitation & Information Statement
2026
May 26
Annual Report
2026
May 22
Proxy Solicitation & Information Statement
2026
May 22
Report Publication Announcement
2026
May 18
Interim / Quarterly Report
2026
May 13
Annual Report
2026
Apr 1
Annual Report
2026
Apr 1
Capital/Financing Update
2026
Mar 2
Regulatory Filings
2026
Feb 26
Regulatory Filings
2026
Jan 26